Payment overview · 2025
General Payments
$1,217.63
48 reported records · 17 companies
Healthcare provider profile · identity verified
Sekar Natarajan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JERSEY CITY, NJ · NPI 1164594354
Verified facts
What the public records show
CMS Open Payments records show Sekar Natarajan, M.D. received $1,217.63 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $251.08 | 20.6% | 14 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $172.61 | 14.2% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $128.75 | 10.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$103.19 | 8.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.76 | 7.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.19 | 7.6% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $66.33 | 5.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.24 | 5.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.24 | 4.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.99 | 3.0% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $34.46 | 2.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.96 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.78 | 2.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.72 | 1.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.83 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.18 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.32 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,217.63 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $172.61 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $172.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $172.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $172.61 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $128.75 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $108.60 | 6 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $103.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.58 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $66.33 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.24 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.05 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.05 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.04 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $52.93 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.03 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.78 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| GLOPERBA Normalized: gloperba |
Drug | SCILEX PHARMACEUTICALS INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 261 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
261 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
137 | 35 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
261 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 787 | 233 |
| Atorvastatin Calcium | Atorvastatin Calcium | 662 | 195 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 539 | 160 |
| Losartan Potassium | Losartan Potassium | 539 | 157 |
| Metformin Hcl | Metformin Hcl | 539 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 98 |
| Gabapentin | Gabapentin | 297 | 101 |
| Montelukast Sodium | Montelukast Sodium | 285 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 80 |
| Simvastatin | Simvastatin | 271 | 82 |
| Jardiance | Empagliflozin | 261 | 68 |
| Omeprazole | Omeprazole | 254 | 83 |
| Furosemide | Furosemide | 246 | 67 |
| Alprazolam | Alprazolam | 244 | 50 |
| Eliquis | Apixaban | 236 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 235 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 226 | 77 |
| Alendronate Sodium | Alendronate Sodium | 218 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 69 |
| Januvia | Sitagliptin Phosphate | 214 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 198 | 61 |
| Azithromycin | Azithromycin | 172 | 125 |
| Carvedilol | Carvedilol | 168 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 54 |
| Famotidine | Famotidine | 167 | 51 |
| Glipizide | Glipizide | 138 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 35 |
| Trazodone Hcl | Trazodone Hcl | 133 | 35 |
| Ozempic | Semaglutide | 132 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 39 |
| Lidocaine | Lidocaine | 127 | 61 |
| Glimepiride | Glimepiride | 115 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 35 |
| Donepezil Hcl | Donepezil Hcl | 102 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 99 | 52 |
| Pregabalin | Pregabalin | 97 | 22 |
| Meclizine Hcl | Meclizine Hcl | 95 | 42 |
| Methylprednisolone | Methylprednisolone | 95 | 65 |
| Lisinopril | Lisinopril | 91 | 30 |
| Glipizide Er | Glipizide | 90 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 24 |
| Prednisone | Prednisone | 80 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 23 |
| Allopurinol | Allopurinol | 76 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 24 |
| Mirtazapine | Mirtazapine | 75 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 74 | 15 |
| Potassium Chloride | Potassium Chloride | 73 | 21 |
| Ezetimibe | Ezetimibe | 72 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 19 |
| Farxiga | Dapagliflozin Propanediol | 70 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 35 |
| Meloxicam | Meloxicam | 63 | 27 |
| Metformin Hcl Er | Metformin Hcl | 63 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 62 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 20 |
| Tramadol Hcl | Tramadol Hcl | 60 | 18 |
| Finasteride | Finasteride | 59 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 41 |
| Linzess | Linaclotide | 56 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 45 |
| Mupirocin | Mupirocin | 54 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 14 |
| Ibuprofen | Ibuprofen | 52 | 24 |
| Atenolol | Atenolol | 51 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 49 | 15 |
| Lorazepam | Lorazepam | 49 | 12 |
| Valsartan | Valsartan | 47 | 16 |
| Lactulose | Lactulose | 46 | 25 |
| Mometasone Furoate | Mometasone Furoate | 45 | 20 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 15 |
| Telmisartan | Telmisartan | 39 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 11 |
| Chlorthalidone | Chlorthalidone | 35 | 12 |
| Latanoprost | Latanoprost | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 18 |
| Cephalexin | Cephalexin | 33 | 30 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Roflumilast | Roflumilast | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 31 | 12 |
| Colchicine | Colchicine | 30 | 14 |
| Diazepam | Diazepam | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Hydrocortisone | Hydrocortisone | 27 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 19 |
| Megestrol Acetate | Megestrol Acetate | 24 | 11 |
| Naproxen | Naproxen | 24 | 13 |
| Santyl | Collagenase Clostridium Hist. | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Jublia | Efinaconazole | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,217.63 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CHARTIS CATHETER, COBALT DR MRI SURESCAN, Cologuard Collection Kit, Da Vinci Surgical System, FASENRA, GLOPERBA, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, NUCALA, OPSYNVI, OTEZLA, Ozempic, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, REPATHA, Rybelsus, SPRAVATO, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZTLido | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error